🇺🇸 FDA
Pipeline program

GLPG CAR T-cell therapy

LTF-CL-001

Phase 3 gene_therapy active

Quick answer

GLPG CAR T-cell therapy for Hematological Malignancies is a Phase 3 program (gene_therapy) at Lakefront Biotherapeutics NV with 1 ClinicalTrials.gov record(s).

Program details

Company
Lakefront Biotherapeutics NV
Indication
Hematological Malignancies
Phase
Phase 3
Modality
gene_therapy
Status
active

Clinical trials